BioScrip Inc. (NASDAQ:BIOS)’s share price fell 7.6% during trading on Tuesday . The stock traded as low as $2.43 and last traded at $2.43, with a volume of 285,845 shares traded. The stock had previously closed at $2.63.

Separately, Zacks Investment Research downgraded shares of BioScrip from a “hold” rating to a “sell” rating in a research note on Wednesday, May 11th.

The company has a 50-day moving average price of $2.60 and a 200 day moving average price of $2.20. The stock’s market capitalization is $185.02 million.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.05. The company had revenue of $238.50 million for the quarter, compared to analyst estimates of $232.38 million. The business’s revenue for the quarter was down 2.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.17) earnings per share. Analysts expect that BioScrip Inc. will post ($0.20) EPS for the current year.

In related news, Director David W. Golding purchased 12,500 shares of the business’s stock in a transaction on Friday, June 17th. The shares were bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the completion of the purchase, the director now directly owns 42,500 shares in the company, valued at approximately $105,400. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Coliseum Capital Management, L purchased 4,200,000 shares of the business’s stock in a transaction on Wednesday, June 22nd. The shares were bought at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The disclosure for this purchase can be found here.

A number of institutional investors recently bought and sold shares of the company. Diamond Hill Capital Management Inc. increased its position in BioScrip by 2.5% in the fourth quarter. Diamond Hill Capital Management Inc. now owns 3,055,476 shares of the company’s stock worth $5,347,000 after buying an additional 74,757 shares in the last quarter. Gabelli Funds LLC increased its position in shares of BioScrip by 22.9% in the fourth quarter. Gabelli Funds LLC now owns 11,430,900 shares of the company’s stock worth $20,004,000 after buying an additional 2,132,060 shares in the last quarter. Finally, Gamco Investors INC. ET AL increased its position in shares of BioScrip by 1.4% in the fourth quarter. Gamco Investors INC. ET AL now owns 864,850 shares of the company’s stock worth $1,513,000 after buying an additional 12,250 shares in the last quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.